Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Lupin Receives Final Approval to Market Generic Ultram® ER

August 31, 2011 By Bio-Medicine.Org

BALTIMORE, Aug. 31, 2011 /PRNewswire/ — Lupin
Pharmaceuticals, Inc. (LPI) today announced that it has received
final approval from the United States Food and Drug Administration
(U.S. FDA) for its Abbreviated New Drug Application (ANDA) for
Tramadol Hydrochloride Extended-Release Tablets, 100, 200 and 300
mg strengths.   Lupin will begin shipping its Tramadol ER
shortly.

Tramadol HCl ER is a centrally acting synthetic analgesic in an
extended release formulation.  It is the generic equivalent to
Ortho-McNeil’s Ultram®* ER Tablets and is indicated for the
management of moderate to moderately severe chronic pain in adults
who require around-the-clock treatment of their pain for an
extended period of time.  Tramadol HCl ER tablets had annual
sales of approximately $132 million for the twelve months ended
June 2011 based on IMS Health sales data.

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation
led transnational pharmaceutical company producing a wide range of
quality, affordable generic and branded formulations and APIs. The
Company today has significant market share in Cardiovasculars,
Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and
NSAIDs in addition holding global leadership positions in the
Anti-TB and Cephalosporins space.  

Today, Lupin is the 5th largest and fastest growing generics
player in the US (by prescriptions), the only Asian company to
achieve that distinction.   The company is also the fastest
growing top 10 pharmaceutical player in India, Japan and South
Africa. (IMS Health)

For the financial year ended March 2011, Lupin’s Consolidated
Revenues and Profit after Tax were Rs.57,068 million USD 1.28
Billion) and Rs. 8,626  million (USD 193 million)
 respectively.  Please visit http://www.lupinworld.com for
more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is t

‘/>”/>

SOURCE

Related Articles Read More >

Connected device design for the real world: Managing the development process
A portrait of ResMed President and COO Rob Douglas
ResMed finds a solution to semiconductor shortage, as well as some humor in it
Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech